



# CHRONIC OBSTRUCTIVE PULMONARY DISEASE

by Dr.Swathi Swaroopa. B



# MORPHOLOGY OF LUNGS



# INTRODUCTION

- ❖ Chronic obstructive pulmonary disease (**COPD**) is characterized by airflow limitation that is not fully reversible.
- ❖ The airflow limitation is usually both **progressive** and associated with an **abnormal inflammatory** response of the lungs.
- ❖ **Cigarette smoking (> 20 PACK YEAR)** is the primary cause of COPD
- ❖ Chronic obstructive pulmonary disease generally refers to **Emphysema** or **Chronic bronchitis**.

- ❖ **Emphysema** is characterized by **alveolar wall destruction** and abnormal, permanent enlargement of air–space.
- ❖ **Chronic bronchitis** associated with chronic or recurrent excess **mucus secretion into the bronchial tree** with **chronic cough** for at least **3 months for 2 consecutive years**.



# **PATHOLOGICAL CHANGES**

**Effect 4 different compartments of lungs:**

- Central airways
- Peripheral airways
- Lung parenchyma ( Bronchioles, alveoli, capillaries)
- Pulmonary vasculature


# INFLAMMATION

```
graph TD; A[INFLAMMATION] --> B[Small airway disease]; A --> C[Parenchymal destruction]; B --> D[AIRFLOW LIMITATION]; C --> D;
```



## Small airway disease

Airway inflammation  
Airway remodeling



## Parenchymal destruction

Loss of alveolar attachments  
Decrease of elastic recoil



# AIRFLOW LIMITATION

# PATHOPHYSIOLOGY

- Noxious Agent
- Inflammation
- Hyperinflation and Hypersecretion
- Airflow Obstruction
- Gas exchange abnormalities

1. Noxious particles and gas inhalation



Activation of neutrophils, macrophages, and CD8 + lymphocytes,



Release tumor necrosis factor- $\alpha$  , interleukin-8, and leukotriene B



Inflammation



Increased number and size of goblet cells and mucus glands



Smooth muscle& connective tissue thickening in airways



Scarring and fibrosis.



## 2.Oxidative stress



Increased oxidants



Damage various proteins and lipids



Cell and tissue damage.

OXIDANTS → Promote inflammation



Inhibit antiprotease activity.



Increase protease-antiprotease imbalance

# Proteases and antiproteases imbalance

- Antiprotease  $\alpha$ 1-antitrypsin (AAT) is an antiprotease enzyme which inhibit the proteases (neutrophil elastase).
- Neutrophil elastase is a potent elastolytic enzyme that attack elastin which leads to tissue damage and loss of elasticity.
- Elastin is a major component of alveolar walls.
- Cigarette smoke activate and attract inflammatory cells into the lung, thereby promoting the release of proteases such as **elastase**.
- Other proteases, including **cathepsins** and **metalloproteinases**.
- A **hereditary deficiency of AAT** results in an increased risk for premature development of emphysema.

**Cigarette smoke**  
Biomass particles and  
particulates

Host factors and  
amplifying mechanisms

Anti-oxidants

Anti-proteinases


**Lung  
inflammation**

Oxidative stress


Proteinases

COPD pathology

Repair  
mechanisms




# BRONCHIAL WALL



# CHRONIC BRONCHITIS

## Bronchitis



- Excess mucous secretions
- Inflamed lung endothelium
- Damaged cilia
- Tissue destruction
- Airway obstruction
- Decreases gas exchange
- Infections
- Hypoxemia
- Pulmonary hypertension
- Polycythemia

# EMPHYSEMA



- Destructive enlargement of air sacs
- Dilation and destruction
- Impaired gas exchange
- Breakdown of elastin
- Loss of elasticity
- Lack of alpha1 anti trypsin

## 2 types

### **CENTRILOBULAR:**

Dilation & destruction of bronchioles, alveolar ducts, alveoli. In COPD

### **PANACINAR:**

Destruction of whole acinus ( airway ending). In alpha1 antitrypsin deficiency.

- **Centrilobular emphysema** that primarily affects respiratory bronchioles
- **Panlobular emphysema** is seen in AAT deficiency and extends to the alveolar ducts and sacs.



## PINK PUFFERS



**EMPHYSEMA**

## BLUE BLOATERS




**CHRONIC BRONCHITIS**



# ***STRUCTURAL CHANGES IN ALVEOLI***



**Normal**



**Bronchitis**



**Emphysema**

# RISK FACTORS

## Host Factors

- Genetic predisposition (alpha1-antitrypsin)
- Airway hyper responsiveness
- Impaired lung growth

## Exposures

- Environmental tobacco smoke
- Occupational dusts and chemicals
- Air pollution

# AETIOLOGY

## 1. Smoking

Major cause of COPD and risk increases

**pack years** = Number of cigarettes per day x number of years smoked ÷ 20

## 2. Age

Increasing age results in ventilatory impairment

## 3. Gender

Women have greater airway reactivity and experience faster declines in FEV1 and are at more risk than men.

## 4. Occupation

Coal and gold mining, cement & cotton industries, farming and grain handling.

# Aetiology ...

## 5. Genetic factor

Deficiency of  $\alpha_1$  antitrypsin ( *strongest risk factor*)

Genetic disorders involving tissue necrosis factor,

## 6. Air pollution

Death rates are higher in urban areas than in rural areas

Indoor air pollution from burning fuel biomass ( *In underdeveloped areas*)

## 7. Socio-economic status

More common in individuals of low socio-economic status


## 8. Airway- hyper responsiveness & allergies

Smokers show high IgE & eosinophils & airway hyper responsiveness

# SYMPTOMS

- Chronic cough
- Dyspnea
- Sputum production
- Bluish discoloration of lips and nail beds
- Increased resting respiratory rate
- Shallow breathing
- Pursed lips during expiration
- Weight loss


## ASTHMA



Bronchoconstriction and  
airway hyperresponsiveness

Reversible

## COPD



Small airway fibrosis and  
alveolar destruction

Not fully  
reversible

**Airflow Limitation**

Characteristic	Asthma	COPD
Age at onset	Usually < 40 yr	Usually > 40 yr
Smoking history	Not causal, but worsens control	Usually >10 pack-years
Sputum production	Infrequent	Common
Allergies	Common	Infrequent
Clinical symptoms	Intermittent and variable	Persistent and progressive
Course of disease	Stable (with exacerbations)	Progressive worsening (with exacerbations)
Importance of nonrespiratory comorbid illnesses	Not usually important	Often important
Spirometry results	Often normalize over time	May improve, but do not normalize over time
Airway inflammation	Eosinophilic	Neutrophilic

\*Adapted with permission from the *Canadian Pharmacists Journal*: 140[Suppl 3], 2007.<sup>22</sup>

# CLINICAL PRESENTATION

## Symptoms

- Chronic cough
- Sputum production
- Dyspnea

## Exposure to Risk Factors

- Tobacco smoke
- $\alpha_1$ -Antitrypsin deficiency
- Occupational hazards

## Physical Examination

- Cyanosis of mucosal membranes
- Barrel chest
- Increased resting respiratory rate
- Shallow breathing
- Pursed lips during expiration
- Use of accessory respiratory muscles

## Diagnostic Tests

- Spirometry with reversibility testing
- Radiograph of chest
- Arterial blood gas (not routine)



## **Symptoms**

- Increased sputum volume
- Acutely worsening dyspnea
- Chest tightness
- Presence of purulent sputum
- Increased need for bronchodilators
- Malaise, fatigue
- Decreased exercise tolerance

## **Physical Examination**

- Fever
- Wheezing, decreased breath sounds

## **Diagnostic Tests**

- Sputum sample for Gram stain and culture
- Chest radiograph to evaluate for new infiltrates

**TABLE 29-5****Classification of Chronic Obstructive Pulmonary Disease Severity****Stage I: mild**

$FEV_1/FVC < 70\%$

$FEV_1 \geq 80\%$

With or without symptoms

**Stage II: moderate**

$FEV_1/FVC < 70\%$

$50\% < FEV_1 < 80\%$

With or without symptoms

**Stage III: severe**

$FEV_1/FVC < 70\%$

$30\% < FEV_1 < 50\%$

With or without symptoms

**Stage IV: very severe**

$FEV_1/FVC < 70\%$


$FEV_1 < 30\%$  or  $< 50\%$  with presence of chronic respiratory failure or right heart failure

**TABLE 29-7**

## Staging Acute Exacerbations of Chronic Obstructive Pulmonary Disease<sup>a</sup>

Mild (type 1)	One cardinal symptom <sup>a</sup> plus at least one of the following: URTI within 5 days, fever without other explanation, increased wheezing, increased cough, increase in respiratory or heart rate >20% above baseline
Moderate (type 2)	Two cardinal symptoms <sup>a</sup>
Severe (type 3)	Three cardinal symptoms <sup>a</sup>

# SPIROMETER



**TABLE 29-6****Modified Medical Research Council (MRC)  
Dyspnea Scale**

Grade 0	No dyspnea	Not troubled by breathlessness except with strenuous exercise
Grade 1	Slight dyspnea	Troubled by shortness of breath when hurrying on a level surface or walking up a slight hill
Grade 2	Moderate dyspnea	Walks slower than normal based on age on a level surface due to breathlessness or has to stop for breath when walking on level surface at own pace
Grade 3	Severe dyspnea	Stops for breath after walking 100 yards or after a few minutes on a level surface
Grade 4	Very severe dyspnea	Too breathless to leave the house or becomes breathless while dressing or undressing